NetworkNewsBreaks – Genprex Inc. (NASDAQ: GNPX)
Post# of 231
(Total Views: 110)
Posted On: 03/25/2024 4:29:05 PM
NetworkNewsBreaks – Genprex Inc. (NASDAQ: GNPX) Closes on $6.5M Registered Direct Offering
Genprex (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, has closed on its registered direct offering. The offering, which was priced in accordance with NASDAQ guidelines, iincluded the sale and issuance of 1,542,112 shares of common stock (or prefunded warrants in lieu thereof) and warrants to purchase up to 1,542,112 shares of common stock. Pricing was $4.215 per share of common stock (or prefunded warrant) and accompanying warrant, resulting in approximately $6.5 million before deducting typical fees and offering expenses. According to the announcement, the warrants have an exercise price of $4.09 per share and are exercisable on the date of issuance; they will expire five years following the date of issuance. Genprex plans to use the funds from this offering for working capital and general corporate purposes. In addition, the company amended certain existing warrants to purchase up to an aggregate of 194,248 shares of GNPX common stock that were previously issued to investors in March 2023 and July 2023. H.C. Wainwright & Co. acted as the exclusive placement agent for the offering.
NOTE TO INVESTORS: The latest news and updates relating to GNPX are available in the company’s newsroom at http://nnw.fm/GNPX
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
Genprex (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, has closed on its registered direct offering. The offering, which was priced in accordance with NASDAQ guidelines, iincluded the sale and issuance of 1,542,112 shares of common stock (or prefunded warrants in lieu thereof) and warrants to purchase up to 1,542,112 shares of common stock. Pricing was $4.215 per share of common stock (or prefunded warrant) and accompanying warrant, resulting in approximately $6.5 million before deducting typical fees and offering expenses. According to the announcement, the warrants have an exercise price of $4.09 per share and are exercisable on the date of issuance; they will expire five years following the date of issuance. Genprex plans to use the funds from this offering for working capital and general corporate purposes. In addition, the company amended certain existing warrants to purchase up to an aggregate of 194,248 shares of GNPX common stock that were previously issued to investors in March 2023 and July 2023. H.C. Wainwright & Co. acted as the exclusive placement agent for the offering.
NOTE TO INVESTORS: The latest news and updates relating to GNPX are available in the company’s newsroom at http://nnw.fm/GNPX
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
(0)
(0)